
Understanding GLP-1-Related Hair Loss: Causes and Treatment Options
Arora Insights
GLP-1 medications, including semaglutide and tirzepatide, have become important tools in medical weight management. While many patients experience meaningful improvements in weight and metabolic health, some also report an unexpected concern: increased hair shedding.
Hair loss can be particularly distressing for patients who are otherwise responding well to treatment. Understanding why it occurs, how long it may last, and which interventions may help is an important part of comprehensive GLP-1 care.
Although the relationship between GLP-1 medications and hair loss is still being studied, rapid weight loss and changes in nutritional intake are recognized contributors. Identifying these factors early can help providers develop appropriate treatment plans and support patients throughout their weight management journey.
Why does hair loss occur during GLP-1 treatment?
Hair loss reported during GLP-1 treatment is frequently associated with the physiological changes that accompany significant weight loss rather than a clearly established direct effect of the medication on hair follicles.
One potential cause is telogen effluvium, a form of temporary hair shedding that occurs when physical or metabolic stress disrupts the normal hair growth cycle.
Under typical conditions, hair follicles move through growth, transition, and resting phases. Significant weight loss, reduced caloric intake, illness, or nutritional deficiencies can cause a greater proportion of follicles to enter the resting phase. Increased shedding may become noticeable approximately two to three months after the triggering event.
Several factors may contribute to hair loss during GLP-1 treatment:
- Rapid weight loss: Significant changes in body weight can create physiological stress that affects the hair growth cycle.
- Reduced caloric intake: Appetite suppression may result in patients consuming substantially fewer calories than their bodies require.
- Inadequate protein consumption: Reduced food intake can make it difficult to meet protein requirements necessary for normal tissue maintenance and hair growth.
- Nutritional deficiencies: Insufficient intake or low levels of certain nutrients, including iron and zinc, may contribute to increased shedding.
- Research is ongoing to determine whether GLP-1 medications may influence hair loss through additional mechanisms independent of weight loss.
Addressing protein intake and nutritional deficiencies
When evaluating hair loss in patients receiving GLP-1 therapy, nutritional intake is an important starting point. GLP-1 medications reduce appetite and increase satiety, which can make it challenging for some patients to consume adequate amounts of protein and other essential nutrients.
Hair is primarily composed of keratin, a structural protein. Inadequate protein intake can interfere with normal hair growth and contribute to shedding, particularly during periods of rapid weight loss. Increasing protein intake is often one of the first recommendations for patients experiencing hair loss during GLP-1 treatment, especially when dietary assessment suggests inadequate consumption.
Patients should work with their healthcare provider to establish individualized protein goals based on their nutritional needs, medical history, and weight management plan. Practical strategies may include prioritizing protein-rich foods, incorporating smaller protein-focused meals throughout the day, and considering protein supplements when appropriate.
For patients experiencing significant or persistent shedding, additional evaluation may be necessary to identify contributing deficiencies or underlying medical conditions. Correcting nutritional deficiencies can support hair recovery, although improvement is not immediate. Hair follicles require time to return to their normal growth cycle.
Can topical minoxidil help with GLP-1-related hair loss?
When nutritional interventions alone are insufficient, topical minoxidil may be considered as an additional treatment option.
Topical minoxidil 5% foam is an established treatment for certain forms of hair loss, particularly androgenetic alopecia, or pattern hair loss. Minoxidil supports hair growth by influencing the hair follicle growth cycle and prolonging the active growth phase. It is commonly used to address progressive thinning and support hair regrowth.
Although minoxidil is widely used for pattern hair loss, evidence supporting its effectiveness specifically for acute telogen effluvium is more limited. Treatment decisions should therefore account for the patient's underlying diagnosis, medical history, and clinical presentation.
Patients considering minoxidil should understand that visible results typically require several months of consistent use. Temporary increased shedding may also occur during the initial stages of treatment.
Additional treatments for hair loss
Depending on the underlying cause, additional treatments may be considered alongside nutritional interventions and minoxidil.
Ketoconazole 2% shampoo
Ketoconazole is a prescription-strength antifungal shampoo commonly used to treat scalp conditions such as seborrheic dermatitis. Addressing inflammation and other scalp concerns may support overall scalp health, although ketoconazole is not an established primary treatment for telogen effluvium.
Daily scalp massage
Gentle scalp massage for approximately 15 minutes daily may be incorporated into a supportive hair care routine. While some preliminary research has explored its potential effects on hair thickness, evidence supporting meaningful hair regrowth remains limited.
Finasteride
Finasteride may be considered for appropriately selected patients experiencing androgenetic alopecia. It is sometimes used in combination with topical minoxidil to address pattern hair loss through complementary mechanisms. Treatment requires appropriate evaluation and counseling regarding potential adverse effects and reproductive risks.
Oral minoxidil
Low-dose oral minoxidil may be considered for certain patients experiencing hair loss, particularly those with androgenetic alopecia or who cannot tolerate topical treatments. Originally developed to treat high blood pressure, oral minoxidil is prescribed off-label for hair loss and may help promote hair regrowth. Treatment requires appropriate medical evaluation and monitoring due to potential side effects, including unwanted facial or body hair growth, fluid retention, and changes in blood pressure or heart rate.
Nutraceutical supplements
Hair-focused supplements, including Nutrafol, may be considered as adjunctive options. However, evidence varies by product and formulation, and supplementation should not replace adequate nutrition or treatment of identified deficiencies.
Pumpkin seed oil
Pumpkin seed oil is a plant-derived supplement studied for its potential benefits in supporting hair growth. It contains naturally occurring compounds, including phytosterols, that may influence pathways associated with androgenetic alopecia. Limited clinical research suggests potential benefits for certain types of pattern hair loss, although additional studies are needed to establish its effectiveness. Evidence supporting its use specifically for GLP-1-related hair shedding remains limited.
Red light therapy
Low-level light therapy uses specific wavelengths of light to stimulate cellular activity within hair follicles. Some studies suggest benefits for androgenetic alopecia, although evidence for its effectiveness in GLP-1-associated telogen effluvium remains limited.
The appropriate combination of treatments depends on the type of hair loss, contributing factors, and individual patient needs.
Is GLP-1-related hair loss reversible?
Hair loss caused by telogen effluvium is generally temporary.
Once the underlying trigger has been addressed, excessive shedding often begins to improve over the following months. However, because hair growth occurs gradually, noticeable improvements in hair density may take six months or longer. Recovery timelines vary based on the severity and duration of shedding, nutritional status, and other conditions affecting hair growth.
Not all hair loss experienced during GLP-1 treatment is attributable to telogen effluvium. Thyroid disorders, hormonal changes, nutritional deficiencies, and androgenetic alopecia may also contribute to thinning. Patients experiencing persistent shedding, patchy hair loss, scalp inflammation, or other concerning symptoms should undergo further evaluation to determine the underlying cause.
Patients should not independently discontinue or adjust their GLP-1 medication because of hair loss. Instead, they should discuss their symptoms with their prescribing provider to determine whether nutritional changes, additional testing, or treatment adjustments are appropriate.
Comprehensive care throughout GLP-1 treatment
Effective GLP-1 treatment requires ongoing attention to more than weight loss alone. Nutritional needs, medication tolerance, potential adverse effects, and changes in overall health should remain part of routine patient monitoring.
Hair loss is one example of why individualized clinical guidance matters throughout treatment. Recognizing potential contributing factors, addressing concerns early, and identifying appropriate interventions can help patients make informed decisions about their care.
At Arora Health, physician-led clinical expertise is central to developing and supporting weight management programs. Through medical directorship, nationwide telehealth provider services, clinical protocols, and compliance guidance, Arora helps med spas, wellness clinics, and digital health companies deliver comprehensive patient care.
Our work extends beyond prescribing and patient clearances to helping healthcare organizations establish the clinical infrastructure and guidance needed to manage the full patient experience.
Developing or expanding a GLP-1 program? Connect with the Arora Health team to learn more about our physician-led services and clinical program support.
This article is intended for educational purposes and does not constitute individualized medical advice. Patients should consult a licensed healthcare provider before starting, stopping, or changing any medication or treatment.

Build what's next on a stronger clinical foundation.
Whether you're launching a new clinical program, expanding a clinic, entering new markets, or scaling a digital health platform, Arora helps you build the physician-led clinical and compliance infrastructure to do it responsibly.
